A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
Summary
Third Opinion Trial Synopsis:
This is a study to see if a new medicine called VenDex is safe and works well for people with a type of cancer called multiple myeloma that has come back or that has not gotten better with other treatments. They will compare it to another medicine called PomDex.
This is a study to see if a new medicine called VenDex is safe and works well for people with a type of cancer called multiple myeloma that has come back or that has not gotten better with other treatments. They will compare it to another medicine called PomDex.
*Third Opinion AI Generated Synopsis
Trial Summary
A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: